Cargando…

Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution

None of the clinical trials on migraine conducted thus far have focused on the possibility to modulate the phenomenon of aura. Furthermore, whether proper management of aura results in a better control of the headache phase has been poorly investigated. In the setting of a single-center, pilot, clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Volta, Giorgio Dalla, Zavarise, Paola, Perego, Laura, Savi, Lidia, Pezzini, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803726/
https://www.ncbi.nlm.nih.gov/pubmed/31687058
http://dx.doi.org/10.1155/2019/6320163
_version_ 1783461007911288832
author Volta, Giorgio Dalla
Zavarise, Paola
Perego, Laura
Savi, Lidia
Pezzini, Alessandro
author_facet Volta, Giorgio Dalla
Zavarise, Paola
Perego, Laura
Savi, Lidia
Pezzini, Alessandro
author_sort Volta, Giorgio Dalla
collection PubMed
description None of the clinical trials on migraine conducted thus far have focused on the possibility to modulate the phenomenon of aura. Furthermore, whether proper management of aura results in a better control of the headache phase has been poorly investigated. In the setting of a single-center, pilot, clinical trial, we aimed at comparing the effects of Aurastop (a combination of tanacetum parthenium (150 mg extracted at 0.8% = 1.2 mg di of active parthenolide), griffonia simplicifoila (20 mg of 5-hydroxy tryptophan), and magnesium (185 mg of magnesium pidolatum)) with those of magnesium alone (2.25 grams/tablet, corresponding to 184 mg of Mg++) in the treatment of acute attacks of migraine with aura. Between June 2017 and June 2018, 50 consecutive patients (27/23 male/female; mean age, 31 [18–57] years) with at least 3 episodes of aura per year were included (t(0)). Participants were instructed to keep track of the following 4 episodes of migraine with aura (t(1)) and invited to assume (1) a tablet of Aurastop at the beginning of the following 2 episodes of aura and (2) a magnesium tablet alone at the occurrence of the third and fourth aura attacks. Forty-eight patients (96.0%) had >50% reduction in aura duration when treated with Aurastop vs. 7 patients (14.0%) when treated with magnesium alone (p < 0.001); 48 patients (96.0%) had >50% reduction of aura-related disability when receiving Aurastop vs. 5 patients (10.0%) when treated with magnesium alone (p < 0.001); however, patients receiving Aurastop did not need to take pain killers in 35% of aura attacks vs. 3% when assuming magnesium (p < 0.001). These results support the hypothesis that Aurastop might be effective in interfering with the phenomenon of aura and provide evidence that the clinical benefit attributable to this combination of molecules might be greater than that obtained with single compounds of proven effect on the biology of migraine.
format Online
Article
Text
id pubmed-6803726
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-68037262019-11-04 Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution Volta, Giorgio Dalla Zavarise, Paola Perego, Laura Savi, Lidia Pezzini, Alessandro Pain Res Manag Research Article None of the clinical trials on migraine conducted thus far have focused on the possibility to modulate the phenomenon of aura. Furthermore, whether proper management of aura results in a better control of the headache phase has been poorly investigated. In the setting of a single-center, pilot, clinical trial, we aimed at comparing the effects of Aurastop (a combination of tanacetum parthenium (150 mg extracted at 0.8% = 1.2 mg di of active parthenolide), griffonia simplicifoila (20 mg of 5-hydroxy tryptophan), and magnesium (185 mg of magnesium pidolatum)) with those of magnesium alone (2.25 grams/tablet, corresponding to 184 mg of Mg++) in the treatment of acute attacks of migraine with aura. Between June 2017 and June 2018, 50 consecutive patients (27/23 male/female; mean age, 31 [18–57] years) with at least 3 episodes of aura per year were included (t(0)). Participants were instructed to keep track of the following 4 episodes of migraine with aura (t(1)) and invited to assume (1) a tablet of Aurastop at the beginning of the following 2 episodes of aura and (2) a magnesium tablet alone at the occurrence of the third and fourth aura attacks. Forty-eight patients (96.0%) had >50% reduction in aura duration when treated with Aurastop vs. 7 patients (14.0%) when treated with magnesium alone (p < 0.001); 48 patients (96.0%) had >50% reduction of aura-related disability when receiving Aurastop vs. 5 patients (10.0%) when treated with magnesium alone (p < 0.001); however, patients receiving Aurastop did not need to take pain killers in 35% of aura attacks vs. 3% when assuming magnesium (p < 0.001). These results support the hypothesis that Aurastop might be effective in interfering with the phenomenon of aura and provide evidence that the clinical benefit attributable to this combination of molecules might be greater than that obtained with single compounds of proven effect on the biology of migraine. Hindawi 2019-10-09 /pmc/articles/PMC6803726/ /pubmed/31687058 http://dx.doi.org/10.1155/2019/6320163 Text en Copyright © 2019 Giorgio Dalla Volta et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Volta, Giorgio Dalla
Zavarise, Paola
Perego, Laura
Savi, Lidia
Pezzini, Alessandro
Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution
title Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution
title_full Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution
title_fullStr Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution
title_full_unstemmed Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution
title_short Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution
title_sort comparison of the effect of tanacethum parthenium, 5-hydroxy tryptophan, and magnesium (aurastop) versus magnesium alone on aura phenomenon and its evolution
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803726/
https://www.ncbi.nlm.nih.gov/pubmed/31687058
http://dx.doi.org/10.1155/2019/6320163
work_keys_str_mv AT voltagiorgiodalla comparisonoftheeffectoftanacethumparthenium5hydroxytryptophanandmagnesiumaurastopversusmagnesiumaloneonauraphenomenonanditsevolution
AT zavarisepaola comparisonoftheeffectoftanacethumparthenium5hydroxytryptophanandmagnesiumaurastopversusmagnesiumaloneonauraphenomenonanditsevolution
AT peregolaura comparisonoftheeffectoftanacethumparthenium5hydroxytryptophanandmagnesiumaurastopversusmagnesiumaloneonauraphenomenonanditsevolution
AT savilidia comparisonoftheeffectoftanacethumparthenium5hydroxytryptophanandmagnesiumaurastopversusmagnesiumaloneonauraphenomenonanditsevolution
AT pezzinialessandro comparisonoftheeffectoftanacethumparthenium5hydroxytryptophanandmagnesiumaurastopversusmagnesiumaloneonauraphenomenonanditsevolution